← Home / Ultragenyx Pharmaceutical Inc. (RARE)
Stock Analysis
Ultragenyx Pharmaceutical Inc. (RARE)
RARE
RARE · Market data
24.91 -4.34%
Track RARE in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when RARE price is:
52W Range Position
36%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:44 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
27.01
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
18
●
Management / Board
MEDIUM
RARE board and management update
As reported below, at its Annual Meeting of Stockholders (the “ Annual Meeting ”) on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc.
8-K Filing • SEC EDGAR
MAY
5
●
Financial Results
HIGH
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
(NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed its financial guidance for 2026.
8-K Filing • SEC EDGAR
What's Driving RARE?
📈 Technical recovery is improving
Momentum is Neutral. Watch 27.01 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 23.93 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
36.15
RSI(14)
33.9
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 23.93 and resistance around 27.64. A move through resistance would be needed to materially improve the chart, while a break of support would keep the pressure side dominant.
Price Chart
RARE — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$2.4B
Company size
EV
$2.3B
Debt-adjusted value
P/E
-4.0
Not meaningful
P/S
3.7
Low sales multiple
P/B
-10.4
Not meaningful
EV/Sales
3.4
Low sales multiple
EV/EBIT
-4.1
Not meaningful
P/FCF
-4.9
Not meaningful
FCF Yield
-20.51%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
136.00M
↘ Weak
📈 Net Income
-185.00M
↘ Negative
🧮 EPS (Basic)
-1.84
↘ Negative
Ultragenyx Pharmaceutical Inc.
Related Opportunities